SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-055780
Filing Date
2021-11-01
Accepted
2021-11-01 16:06:10
Documents
58
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0921_lantern.htm   iXBRL 10-Q 795678
2 CERTIFICATION f10q0921ex31-1_lantern.htm EX-31.1 10021
3 CERTIFICATION f10q0921ex31-2_lantern.htm EX-31.2 15206
4 CERTIFICATION f10q0921ex32-1_lantern.htm EX-32.1 3538
5 CERTIFICATION f10q0921ex32-2_lantern.htm EX-32.2 3485
  Complete submission text file 0001213900-21-055780.txt   3816794

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20210930.xsd EX-101.SCH 46666
7 XBRL CALCULATION FILE ltrn-20210930_cal.xml EX-101.CAL 25147
8 XBRL DEFINITION FILE ltrn-20210930_def.xml EX-101.DEF 190235
9 XBRL LABEL FILE ltrn-20210930_lab.xml EX-101.LAB 375489
10 XBRL PRESENTATION FILE ltrn-20210930_pre.xml EX-101.PRE 198272
11 EXTRACTED XBRL INSTANCE DOCUMENT f10q0921_lantern_htm.xml XML 368683
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

IRS No.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 211367168
SIC: 2834 Pharmaceutical Preparations